2024 CSCC Travelling Lectureship
Sponsored by:
Shifting Paradigms:
It’s Time to Change the Way We Diagnose and Treat Type 1 Diabetes
SPEAKER:
Emily K. Sims, MD, MS
- Associate Professor of Pediatrics, Indiana University School of Medicine
- Assistant Director, Wells Center for Pediatric Research
- Associate Director, IU Medical Scientist Training Program
- NIH-funded physician scientist specializing in pediatric endocrinology with a research focus on identification of mechanisms and biomarkers of intrinsic beta cell dysfunction contributing to development of type 1 diabetes (T1D), clinical measurements of beta cell function that can be used to understand T1D heterogeneity and responses to disease-modifying therapies, and application of therapeutics aimed at improving beta cell health in T1D.
Description:
Type 1 diabetes is an autoimmune disease yielding destruction of pancreatic beta cells and leading to insulin deficiency. Treatment over the past 100 years has consisted of insulin replacement once affected patients have passed a critical threshold of beta cell loss. However, screening for autoantibodies to pancreatic islets can diagnose type 1 diabetes in the early presymptomatic stages. Furthermore, novel disease modifying therapies may allow for the delay of insulin requirements in these presymptomatic individuals. These advances are changing the way that providers can diagnose and treat patients affected by type 1 diabetes.
Learning objectives:
At the end of this session, participants will be able to understand:
1) Type 1 diabetes can be identified in a presymptomatic phase.
2) Presymptomatic type 1 diabetes typically progresses through a series of stages.
3) Disease modifying therapies allow for intervention in the natural history of type 1 diabetes.
Dates:
- Sept 18, 2024 – 2:00-3:00 PM ET – Quebec/Atlantic Provinces (virtual)
- Oct 11, 2024 – 8:30-9:30 AM ET – OSCC AGM, Toronto, ON (virtual)
- Oct 21, 2024 – 8:00-9:00 AM PT – Vancouver, BC
- Oct 22, 2024 – 12:00-1:00 PM MT – Edmonton, AB